JUBLIA

[{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"}]